Tofacitinib
规格
477600-75-2CAS 号
689-145-4EC 号
3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrileIUPAC 名称
C16H20N6O化学式
312.37 g/mol分子量
Tofacitinib; 477600-75-2; Tasocitinib; 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; CP-690550; CP 690550; Cp-690 free base; tofacitinibum; 3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile; CP690550; 87LA6FU830; CP-690550 FREE BASE; CP-690,550 FREE BASE; CP690,550; CP-690-550; CHEBI:71200; DTXSID90197271; CP-690; 3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; 3-[(3R,4R)-4-methyl-3-[methyl({7H-pyrrolo[2,3-d]pyrimidin-4-yl})amino]piperidin-1-yl]-3-oxopropanenitrile; 3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile; 3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo(2,3-d)pyrimidin-4-yl-, (3R,4R)-; 3-((3R,4R)-4-methyl-3-(methyl((7H-pyrrolo(2,3-d)pyrimidin-4-yl))amino)piperidin-1-yl)-3-oxopropanenitrile; RefChem:6313; JAK inhibitors: tofacitinib; DTXCID00119762; L04AA29; 689-145-4; 1259404-17-5; Tofacitinib (CP-690550,Tasocitinib); 3-((3R,4R)-rel-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; rac-Tofacitinib; Tofacitinib (CP-690550); Tofacitinib [USAN]; C16H20N6O; CHEMBL221959; 1-Piperidinepropanenitrile, 4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-, (3R,4R)-; racemic-tofacitinib; racemic-Tasocitinib; MFCD22628813; Tofacitinib (USAN); MFCD11035919; 3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-1-piperidyl]-3-oxo-propanenitrile; 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile; (+)-TOFACITINIB; Tofacitinib [USAN:INN]; UNII-87LA6FU830; Tofacitinib?; Tofacitinib Base; 3eyg; 3fup; 3lxk; 4oti; (Rac)-Tofacitinib; 1-PIPERIDINEPROPANENITRILE, 4-METHYL-3-(METHYL-7H-PYRROLO(2,3-D)PYRIMIDIN-4-YLAMINO)-.BETA.-OXO-, (3R,4R)-; 1-Piperidinepropanenitrile, 4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-.beta.-oxo-, (3R,4R)-; 3-(4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; MI1; 477600-75-2 (free base); Tofacitinib (Standard); TOFACITINIB [MI]; TOFACITINIB [INN]; TOFACITINIB [VANDF]; PFE-PKIS 25; PFE-PKIS_25; TOFACITINIB [WHO-DD]; SCHEMBL322753; GTPL5677; orb1224990; orb1300872; SCHEMBL29351183; HSDB 8311; EX-A205; UJLAWZDWDVHWOW-YPMHNXCESA-N; GLXC-90307; BDBM50193995; EBC-11351; HY-40354R; NSC782351; NSC800953; AKOS005145814; AKOS005258733; AC-8193; AT43433; CCG-264998; CS-0050; DB08895; FT32555; GS-6106; NSC-782351; NSC-800953; SDCCGSBI-0654407.P002; TOFACITINIB (CONTROLLED RELEASE); NCGC00229511-02; NCGC00229511-04; NCGC00229511-10; NCGC00229511-24; NCGC00229511-25; NCGC00244463-01; 3-[(3R*,4R*)-4-Methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile; HY-40354; NS00069315; T6321; CP- 690 550; D09970; AB01565786_02; EN300-1718468; AR-270/43507983; F050788; Q3530324; BRD-K31283835-001-01-9; BRD-K31283835-048-04-4; (3R,4R)-3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile; (3R,4R)-4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidine propanenitrile; (3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidine-propanenitrile; 1-Piperidinepropanenitrile, 4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-|A-oxo-, (3R,4R)-; 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile citrate; 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]piperidin-1-yl}-3-oxo-propionitrile; 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile; 3-{4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-1-piperidinyl}-3-oxopropanenitrile; REL-3-((3R,4R)-4-METHYL-3-(METHYL(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)AMINO)PIPERIDIN-1-YL)-3-OXOPROPANENITRILE同义词
含有Tofacitinib的产品
잭파즈정10밀리그램(토파시티닙)토파시아정(토파시티닙)잭파즈정5밀리그램(토파시티닙)지에케이정5밀리그램(토파시티닙)토시닙정5밀리그램(토파시티닙)엘란즈정5밀리그램(토파시티닙)젤즈원정5밀리그램(토파시티닙)TofacitinibTOFACITINIB (CP-690550,TASOCITINIB)TofacitinibTofacitinibTofacitinib
第 1/2 页
销售Tofacitinib的公司
한림
한림제약(주)Republic of Korea일양
일양약품(주)Republic of Korea유니
유니메드제약(주)Republic of KoreaHC
Hangzhou Celor Chemical Co.,Ltd.ChinaSD
SHIJIAZHUANG DINGMIN PHARMACEUTICAL SCIENCES CO., LTDChinaHP
Harway Pharma CO., LTDChinaSX
Sichuan Xieli Pharmaceutical Co., Ltd.ChinaCH
Chongqing Huapont Shengchem Pharmaceutical Co., Ltd.China하나
하나제약(주)Republic of Korea(주
(주)킴스제약Republic of Korea第 1/2 页